A5005769474- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Breast Lesions and Carcinomas
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Bone health and treatments
- Neutropenia and Cancer Infections
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Neuroendocrine Tumor Research Advances
- Brain Metastases and Treatment
- Cancer Research and Treatments
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
Curtin University
2016-2025
Breast Cancer Research Foundation
2014-2025
Central Michigan University
2024
Hollywood Orthopaedic Group
2023-2024
Hollywood Private Hospital
2016-2023
Novartis (Switzerland)
2019-2023
Roche (Switzerland)
2010-2023
AstraZeneca (Canada)
2023
Sanofi (France)
2023
Eisai (Japan)
2023
Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and (EGFR), is active in combination with capecitabine women HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. In this trial, we compared lapatinib plus alone such patients.Women HER2-positive, locally advanced or had treatment regimens included an anthracycline, taxane, trastuzumab were randomly assigned receive either therapy...
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated cardiac toxicity. We wanted to evaluate efficacy and safety a new nonanthracycline regimen trastuzumab.We randomly assigned 3222 women HER2-positive early-stage cancer receive doxorubicin cyclophosphamide followed by docetaxel every 3 weeks (AC-T), same plus 52 trastuzumab (AC-T trastuzumab), or carboplatin (TCH). The primary...
The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) negative human epidermal growth factor 2 (HER2).In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy safety selective CDK4/6 inhibitor ribociclib combined with letrozole first-line treatment 668 postmenopausal women HR-positive, HER2-negative recurrent metastatic who had...
The efficacy and safety of combining bevacizumab (7.5 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial.Patients (N = 736) were randomly assigned to 100 mg/m(2) plus either placebo 7.5 mg/kg every 3 weeks. primary end point progression-free survival (PFS); secondary points included best overall response, duration...
Abstract Background: Evaluation of the long-term benefit biologically-based regimens trastuzumab in early breast cancer population, and optimization integration to maximize efficacy minimize cardiac toxicity.Material Methods: We randomized HER2-positive (FISH+) patients with axillary lymph node positive or high risk negative, either standard AC (60/600 mg/m2 q3wk x4) followed by T (100 x 4) two trastuzumab-containing regimens; 1 year TCarbo (75 mg/m2/AUC6 6) year. Patients were prospectively...
Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of cancer. Our randomized phase II study investigated cisplatin with or without cetuximab this setting.Patients who had received no more than one previous chemotherapy regimen were randomly assigned on a 2:1 schedule to receive six cycles plus alone. Patients receiving alone could switch disease progression. The primary end point was overall response rate (ORR)....
Recent data showed improvement in progression-free survival (PFS) when adding everolimus to exemestane patients with advanced breast cancer experiencing recurrence/progression after nonsteroidal aromatase inhibitor (AI) therapy. Here, we report clinical outcomes of combining the mammalian target rapamycin (mTOR) temsirolimus letrozole AI-naive patients.This phase III randomized placebo-controlled study tested efficacy/safety first-line oral 2.5 mg daily/temsirolimus 30 daily (5 days every 2...
To investigate whether sunitinib plus docetaxel improves clinical outcomes for patients with human epidermal growth factor receptor 2 (HER2)/neu-negative advanced breast cancer (ABC) versus alone.In this phase III study, were randomly assigned to open-label combination therapy (sunitinib 37.5 mg/d, days 15 every 3 weeks; and 75 mg/m(2), day 1 weeks) or monotherapy (docetaxel 100 mg/m(2) weeks). Progression-free survival (PFS) was the primary end point.Two hundred ninety-six therapy, 297...
PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel Patients HER2-Positive Metastatic Breast Cancer] evaluated first-line bevacizumab-containing therapy for human epidermal growth factor receptor 2 (HER2) -positive locally recurrent/metastatic breast cancer (LR/MBC). PATIENTS AND METHODS with measurable/evaluable HER2-positive LR/MBC who had not received trastuzumab or chemotherapy were stratified by prior adjuvant trastuzumab,...
BackgroundThe ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC).Patients and MethodsExteNET was a multicenter, randomized, double-blind, phase III of 2840 HER2+ eBC after neoadjuvant/adjuvant trastuzumab-based therapy. Patients were stratified by HR status...
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
The primary objective was to evaluate intracranial response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary hormone receptor-positive (HR+) metastatic breast cancer (MBC). Secondary objectives evaluated extracranial response, pharmacokinetics, tissue exposure, and safety.This nonrandomized, phase II study (NCT02308020) enrolled tumor subtype-specific cohorts A-D: A (HR+, HER2- MBC), B HER2+ C (HR+ MBC LM), D (brain surgical resection)....
Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant, receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) advanced breast cancer (aBC).
Abstract Introduction This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel patients metastatic triple-negative breast cancer (mTNBC). Methods Eligible who had received ≤1 prior cytotoxic regimen for mTNBC were treated olaparib 200 mg bid continuously plus weekly 90 mg/m 2 three weeks per four-week cycle. Dose modifications large proportion due to neutropenia resulted...
Combining bevacizumab with first-line chemotherapy significantly improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC). However, identification of patients benefitting most from remains elusive. The AVADO trial included an extensive optional exploratory biomarker programme. Patients mBC were randomised to receive docetaxel placebo or bevacizumab. primary end point was PFS. Plasma samples analysed using a multiplex ELISA. Blood mRNA expression assessed...